Oculis Holding AG (OCS) Retained Earnings (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Retained Earnings of -$527.9 million in Q1 2026, down 9.72% quarter-over-quarter from -$481.1 million in Q4 2025, and down 48.88% on a YoY basis from -$1.0 billion in Q1 2025.
Oculis Holding AG (OCS) Retained Earnings (2021 - 2026) Analysis & Trends
Oculis Holding AG's Retained Earnings history runs 6 years deep, the most recent figure standing at -$527.9 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 48.88% year-over-year to -$527.9 million; the TTM figure through Mar 2026 stood at -$527.9 million (down 48.88% YoY), while the FY2025 annual figure was -$481.1 million, down 47.59% from the prior year.
- Retained Earnings was -$527.9 million for Q1 2026 at Oculis Holding AG, down from -$481.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$115.2 million in Q4 2022 to a low of -$527.9 million in Q1 2026.
- Historically, Retained Earnings has averaged -$315.6 million across 5 years, with a median of -$296.5 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings slumped 95.51% in 2023, then slumped 38.55% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$115.2 million in 2022, then tumbled by 95.51% to -$225.2 million in 2023, then sank by 44.73% to -$326.0 million in 2024, then sank by 47.59% to -$481.1 million in 2025, then fell by 9.72% to -$527.9 million in 2026.
- The last three Retained Earnings figures came in at -$527.9 million (Q1 2026), -$481.1 million (Q4 2025), and -$451.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -838.07 Mn |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | -527.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -527.87 Mn |
| Dec 31, 2025 | -481.09 Mn |
| Sep 30, 2025 | -451.29 Mn |
| Jun 30, 2025 | -415.69 Mn |
| Mar 31, 2025 | -354.55 Mn |
| Dec 31, 2024 | -325.97 Mn |
| Sep 30, 2024 | -296.52 Mn |
| Jun 30, 2024 | -261.75 Mn |
| Mar 31, 2024 | -247.32 Mn |
| Dec 31, 2023 | -225.22 Mn |
| Sep 30, 2023 | -212.03 Mn |
| Jun 30, 2023 | -188.93 Mn |
| Dec 31, 2022 | -115.20 Mn |
| Dec 31, 2021 | -78.39 Mn |